Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI response includes on-label indications and dosing references but contains numerous stewardship-related claims not supported by the FDA-approved TIGACIL label. Overall, it shows partial alignment with the official prescribing information.
Category Scores
Accurate Statements
Pre-set approved indications or recommended situations for tigecycline use.
1. Indications and Usage
Tightening how they choose the dose.
2. Dosage and Administration
Correct tigecycline usage depends on giving the right regimen for the patient population being treated and adjusting for renal/hepatic considerations as applicable to local guidance.
2. Dosage and Administration; 8. Use in Specific Populations
Shorter courses or earlier switching when the infection responds and cultures allow.
2.1
Fewer prolonged exposures to drugs that carry risk of adverse effects when they are not needed.
2.1
Unsupported Statements
Stewardship programs for tigecycline focus on using the drug only when it’s the right match for the infection and the patient.
Not described in the prescribing information.
Tightening when clinicians start tigecycline.
Not described in the prescribing information.
Tightening when they stop or switch therapy based on response and culture results.
Not described in the prescribing information.
The main goals are to reduce avoidable use.
Not described in the prescribing information.
The main goals are to limit resistance pressure.
Not described in the prescribing information.
The main goals are to avoid exposing patients to toxicity they may not need.
Not described in the prescribing information.
Tigecycline is restricted to specific clinical scenarios—most commonly when narrower options aren’t appropriate or when resistant organisms are suspected/confirmed.
Not described in the prescribing information.
Clinical criteria that require documentation of infection source, severity, and why alternatives are unsuitable.
Not described in the prescribing information.
Culture and sensitivity review so tigecycline is continued only if it is still the best active option.
Not described in the prescribing information.
Standard dosing protocols embedded in order sets.
Not described in the prescribing information.
Real-time dose checking by pharmacists or review teams.
Not described in the prescribing information.
Feedback to prescribers when dosing deviates from the protocol or when an order lacks required clinical justification.
Not described in the prescribing information.
A big driver of correct use is avoiding set-and-forget therapy.
Not described in the prescribing information.
Frequent case reviews within the first 48–72 hours and then periodically.
Not described in the prescribing information.
Culture results and clinical trajectory to de-escalate to narrower agents when possible.
Not described in the prescribing information.
Stop rules based on improvement, negative cultures, or completion of the intended treatment course.
Not described in the prescribing information.
Guidance on switching from IV to oral therapy when an appropriate oral option exists when clinically suitable.
Not described in the prescribing information.
Audit-and-feedback is used to improve tigecycline prescribing by reviewing use patterns and providing targeted recommendations.
Not described in the prescribing information.
Audit-and-feedback includes assessment of whether tigecycline was started before adequate diagnostic cultures.
Not described in the prescribing information.
Audit-and-feedback assesses whether dosing and frequency match the protocol.
Not described in the prescribing information.
Audit-and-feedback assesses whether the patient still needs tigecycline after early results.
Not described in the prescribing information.
Audit-and-feedback assesses whether therapy could be shortened or changed to a more specific agent.
Not described in the prescribing information.
Tigecycline can be overused when clinicians choose it broadly for empiric coverage without a clear rationale.
Not described in the prescribing information.
A documented plan includes what organisms are being targeted and why.
Not described in the prescribing information.
A documented plan includes what alternative treatments were considered.
Not described in the prescribing information.
A documented plan includes when re-assessment will happen after cultures return.
Not described in the prescribing information.
This helps ensure tigecycline is reserved for situations where it is truly warranted rather than used as a default broad agent.
Not described in the prescribing information.
Earlier diagnostic workups (cultures and source evaluation).
Not described in the prescribing information.
More deliberate selection of antibiotics instead of automatic escalation.
Not described in the prescribing information.
Some stewardship and prescribing guidance is published through hospital antibiotic policies and clinical guidelines.
Not described in the prescribing information.
Contradictions
Important Omissions
Contraindications, boxed warnings, and specific safety-related content (adverse reactions, monitoring, interactions) are not addressed.
Importance:
High
Detailed adverse reaction profile, monitoring recommendations, and drug–drug interaction guidance are not provided.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Evaluating alignment with label content rather than presenting clinical safety recommendations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Stewardship-related claims are not consistently supported by the prescribing information.
Suggested Improvement
Limit statements to on-label indications, dosing (2.1, 2.2, 2.3), hepatic impairment considerations, pediatric dosing when applicable, and Use in Specific Populations (8). Remove or clearly label stewardship-focused content unless explicitly supported by the label; cite the applicable label sections for each claim.